{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["van der Kooi ALF"],"funding":["European Union’s Seventh Framework Programme","European Union’s Health Programme","NCI","Children Cancer Free Foundation","Dutch Cancer Society","NCI NIH HHS"],"pagination":["1120-1133"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7970730"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(4)"],"pubmed_abstract":["<h4>Study question</h4>Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)?<h4>Summary answer</h4>Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy.<h4>What is known already</h4>Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian function might explain this variability.<h4>Study design, size, duration</h4>CCS for the discovery cohort were identified f"],"journal":["Human reproduction (Oxford, England)"],"pubmed_title":["Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function."],"pmcid":["PMC7970730"],"funding_grant_id":["U01 CA195547","602030","2014–2020","768967","20","VU 2006-3622"],"pubmed_authors":["Yasui Y","Chemaitilly W","Uitterlinden AG","van der Pal HJ","Versluys B","Modan-Moses D","Winther JF","Kremer LC","Brooke RJ","Kaspers GL","Bresters D","Dirksen U","van den Heuvel-Eibrink MM","Fossa SD","van Leeuwen FE","de Vries ACH","Haupt R","Laven JSE","Kaiser M","Zolk O","Grabow D","van Dijk M","Kruseova J","Pluijm SMF","van den Berg MH","Ronckers CR","Hudson MM","Loonen JJ","van Dulmen-den Broeder E","Robison LL","Lambalk CB","Tissing WJ","Beerendonk CCM","Berger C","Kaatsch P","Kepak T","Spix C","Krijthe JH","Byrne J","Overbeek A","Broer L","van der Heiden-van der Loo M","van der Kooi ALF","Clemens E"],"additional_accession":[]},"is_claimable":false,"name":"Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function.","description":"<h4>Study question</h4>Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)?<h4>Summary answer</h4>Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy.<h4>What is known already</h4>Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian function might explain this variability.<h4>Study design, size, duration</h4>CCS for the discovery cohort were identified f","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-05-03T09:27:40.617Z","creation":"2024-11-20T17:48:41.498Z"},"accession":"S-EPMC7970730","cross_references":{"pubmed":["33582778"],"doi":["10.1093/humrep/deaa342"]}}